1. Kershaw EE, Flier JS. Adipose tissue as an endocrine organ. J Clin Endocrinol Metab 2004; 89:2548–2556.
2. Kawamata Y, Habata Y, Fukusumi S, Hosoya M, Fujii R, Hinuma S, et al. Molecular properties of apelin: tissue distribution and receptor binding. Biochim Biophys Acta 2001; 1538:162–171.
3. Tatemoto K, Hosoya M, Habata Y, Fujii R, Kakegawa T, Zou MX, et al. Isolation and characterization of a novel endogenous peptide ligand for the human APJ receptor. Biochem Biophys Res Commun 1998; 251:471–476.
4. Masri B, Knibiehler B, Audigier Y. Apelin signaling, a promising pathway from cloning to pharmacology. Cell Signal 2005; 17:415–426.
5. Falcao-Pires I, Leite-Moreira AF. Apelin: a novel neurohumoral modulator of the cardiovascular system: Pathophysiologic importance and potential use as a therapeutic target. Rev Port Cardiol 2005; 24:1263–1276.
6. Daviaud D, Boucher J, Gesta S, Dray C, Guigne C, Quilliot D, et al. TNFalpha up-regulates apelin expression in human and mouse adipose tissue. FASEB J 2006; 20:1528-1530.
7. Kleinz MJ, Davenport AP. Emerging roles of apelin in biology and medicine. Pharmacol Ther 2005; 107:198–211.
8. Xie H, Tang SY, Cui RR, Huang J, Ren XH, Yuan LQ, et al. Apelin and its receptor are expressed in human osteoblasts. Regul Pept 2006; 134:118–125.
9. De Mota N, Reaux-Le Goazigo A, El Messari S, Chartrel N, Roesch D, Dujardin C, et al. Apelin, a potent diuretic neuropeptide counteracting vasopressin actions through inhibition of vasopressin neuron activity and vasopressin release. Proc Natl Acad Sci USA 2004; 101:10464–10469.
10. Higuchi K, Masaki T, Gotoh K, Chiba S, Katsuragi I, Tanaka K,Kakuma T, Yoshimatsu H. Apelin, an APJ receptor ligand, regulates body adiposity and favors the messenger ribonucleic acid expression of uncoupling proteins in mice. Endocrinology 2007; 148: 2690–2697.
11. Boucher J, Masri B, Daviaud D, Gesta S, Guigne C, Mazzucotelli A, et al. Apelin a newly identified adipokine up-regulated by insulin and obesity. Endocrinology 2005; 146:1764–1771.
12. Bruce C. Frier, Deon B. Williams and David C. Wright. mitochondrial content The effects of apelin treatment on skeletal muscle. Am J Physiol Regul Integr Comp Physio 2009; 297:R1761-R1768.
13. Heinonen MV, Purhonen AK, Miettinen P, Paakkonen M, Pirinen E, Alhava E, et al. Apelin, orexin-A and leptin plasma levels in morbid obesity and effect of gastric banding. Regul Pept 2005; 130:7–13.
14. Garcia-Diaz D, Campion J, Milagro FI, Martinez JA. Adiposity dependent apelin gene expression: relationships with oxidative and inflammation markers. Mol Cell Biochem 2007; 305:87–94.
15. Zhang J, Ren CX, Qi YF, Lou LX, Chen L, Zhang LK, et al. Exercise training promotes expression of apelin and APJ of cardiovascular tissues in spontaneously hypertensive rats. Life Sci 2006; 79:1153-1159.
16. Lee DK, Cheng R, Nguyen T, Fan T, Kariyawasam AP, Liu Y, et al. Characterization of apelin, the ligand for the APJ receptor. J Neurochem 2000; 74:34–41
17. Medhurst AD, Jennings CA, Robbins MJ, Davis RP, Ellis C, Winborn KY, et al. Pharmacological and immune-histochemical characterization of the APJ receptor and its endogenous ligand apelin. J Neurochem 2003; 84:1162–1172.
18. Li L, Yang G, Li Q, Tang Y, Yang M, Yang H, et al. Changes and relations of circulating visfatin, apelin, and resistin levels in normal, impaired glucose tolerance, and type 2 diabetic subjects. Exp Clin Endocrinol Diabetes 2006; 114:544–548.
19. Wei L, Hou X, Tatemoto K. Regulation of apelin mRNA expression by insulin and glucocorticoids in mouse 3T3-L1 adipocytes. Regul Pept 2005; 132:27–32.